Hyaluronic acid (HA), an unbranched high molecular weight polysaccharide can now be measured by several immunometric assays. The connective tissues are the main source of HA and it is destroyed mainly in the liver. Very high levels of HA occur in mesothelioma, Wilms' tumour and acute liver failure, and moderate increases in rheumatoid diseases, renal failure and cirrhosis. Local increased production of HA is a feature of several forms of lung disease. HA is an indicator of connective tissue turnover, of the function of the receptor mechanisms for its capture and destruction by the liver, and of the removal of low molecular weight fragments by the kidney.
WhitmanP.Quantitative measurement of Alcian blue-GAG complexes. Biochem J1973; 131: 343–50.
2.
FarndaleRWBarettSayers AJ. A direct spectrophotometric microassay for sulphated glycosaminoglycosides. Conn Tiss Res1982; 9: 247–8.
3.
ManleyGWilliamsU.Urinary excretion of glycosaminoglycans in the various forms of gargoylism. J Clin Pathol1969; 22: 67–75.
4.
PennockCA. A review and selection of simple laboratory methods used for the study of glycoaminoglycan excretion and the diagnosis of mucopolysaccharidoses. J Clin Pathol1976; 29: 111–13.
5.
CatersonBChristnerJEBakerJR. Identification of a monoclonal antibody that specifically recognises corneal and skeletal keratan sulfate. J Biol Chem1983; 258: 8848–54.
6.
HeingardDInerotSWieslanderJA method for the quantification of cartilage proteoglycan structures liberated into the synovial fluid during developing degenerative joint disease. Scand J Clin Lab Invest1985; 45: 421–7.
7.
ThonarEJ-MALenzMEKlintworthGKQuantification of keratan sulfate in blood as a marker of cartilage catabolism. Arthritis Rheumat1985; 28: 1367–76.
8.
RisteliLRisteliJ.Analysis of extracellular matrix proteins in biological fluids. In: CunninghamLW, ed. Methods in Enzymology, Vol 145. New York: Academic Press, 1987; 391–411.
LohmanderLS. Proteoglycans of joint cartilage. In DixonJBirdH, eds. Biochemical Aspects of Rheumatic Diseases: Baillière's Clinical Rheumatology, Vol 2. London: Baillière Tindall pp. 37–62.
11.
LaurentTZFraserJRE. The properties and turnover of hyaluronan. In: EveredDWhelanJ, eds. Functions of the Proteoglycans: Ciba Foundation Symposium, Vol. 124. Chichester: Wiley, 1986; 9–29.
12.
ScottJENewtonDJ. The recovery and characterisation of acid glycosaminoglycans in normal human urine. Connect Tiss Res1975; 3: 157–64.
13.
BreenMWeinsteinHGBlackLJMicroanalysis and characterization of acidic glycosaminoglycans in human tissues. In: WhistlerRLMillerJN, eds. Methods in Carbohydrate Chemistry, Vol 7. New York: Academic Press1976; 101–15.
14.
WarrenCManleyG.Measurement of serum glycosaminoglycans by laser nephelometry. Clin Chim Acta1981; 116: 369–80.
15.
RobozJChahinianAPHollandJFEarly diagnosis and monitoring of transplanted human malignant mesothelioma by serum hyaluronic acid. J Nat Cancer Inst1989; 81: 924–8.
16.
GherezghierTKossMCNordquistREWilkinsonCP. Rapid and sensitive method for the measurement of hyaluronic acid and isomeric chondroitin sulfates using high performance liquid chromatography. J Chromatogr1987; 413: 9–15.
17.
TengbladA.Affinity chromatography on immobilized hyaluronate and its application to the isolation of hyaluronate binding proteins from cartilage. Biochim Biophys Acta1979; 578: 281–9.
18.
LaurentUBGTengbladA.Determination of hyaluronate in biological samples by a specific radioassay technique. Analyt Biochem1980; 109: 386–94.
DelpechBBertrandPMaingonnatC.Immunoenzyme assay of the hyaluronic acid-hyaluronectin interaction: Application to the detection of hyaluronic acid in the serum of normal subjects and cancer patients. Analyt Biochem1985; 149555–65.
21.
LiXQThonarEJMAKundsonW.Accumulation of hyaluronate in lung carcinoma measured by a new hyaluronate ELISA. Connect Tissue Res1985; 19: 243–53.
22.
KongtawelertPGoshP.An enzyme-linked immunosorbent-inhibition assay for quantification of hyaluronan (hyaluronic acid) in biological fluids. Anal Biochem1989; 178: 367–72.
23.
TengbladALaurentUBGLiljaKConcentration and relative molecular mass of hyaluronate in lymph and blood. Biochem J1986; 236: 521–5.
24.
PrehmP.Synthesis of hyaluronate in differentiated teratocarcinoma cells: Mechanism of chain growth. Biochem J1983; 211: 191–8.
25.
YamadaKM. Fibronectin and other structural proteins. In: HayED, ed. Cell Biology of the Extracellular Matrix. New York: Plenum Press. 1981; 95–114.
26.
HormannHJelinickV.Regulation by heparin and hyaluronic acid of fibronectin-dependent association of collagen, type III, with macrophages. Hoppe-Seyler's. Z Physiol Chem1981; 36287–94.
27.
FraserJRAppelgrenLELaurentTC. Tissue uptake of circulating hyaluronic acid. A whole body autoradiographic study. Cell Tissue Res1983; 233: 285–93.
28.
TrevediPPortmanBMowatAP. Serum hyaluronic acid (HA)–a new test of liver function. Hepatology, in press.
29.
LaurentTCLiljaKBrunnbergLUrinary excretion of hyaluronan in man. Scand J Clin Lab Invest1987; 47: 793–9.
30.
LindqvistUEngstrom-LaurentANybergAThe diurnal variation of serum hyluronan in health and disease. Scand J Clin Lab Invest1988; 48: 765–70.
31.
ChevrierAGirardNDelpechBInhibition of active E rosette forming T lymphocytes by hyaluronic acid. Evidence for a receptor for hyaluronic acid on a lymphocyte subpopulation. Biochem Pharmacother1982; 36: 100–3.
32.
BergHBordinBHesselvikFElevated levels of hyaluronan in septicaemia. Scand J Clin Lab Invest1988; 48: 727–32.
33.
WuAHBParkerOSFordL.Hyperviscosity caused by hyaluronic acid in serum in a case of Wilms' tumour. Clin Chem1984; 30: 914–16.
34.
WestIDCKumarS.Hyaluronan and angiogenesis. In: EveredDWhelanJ, eds. The Biology of Hyaluronan: CIBA Symposium, Vol 143. Chichester: Wiley, 1989; 187–207.
35.
WaxterBEisensteinRBattiforaH.Electrophoresis of tissue glycosaminoglycans as an aid to diagnosis of mesotheliomas. Cancer1979; 44: 221–7.
36.
ChinBChurgATengbladAAnalysis of hyaluronic acid in the diagnosis of malignant mesothelioma. Cancer1984; 54: 2195–9.
37.
DahlIMLaurentTC. Concentration of hyaluronan in the serum of untreated cancer patients with special reference to patients with mesothelioma. Cancer1988; 62: 326–30.
38.
PettersonTFrosethBRiskaHConcentration of hyaluronic acid in pleural fluid as a diagnostic aid for malignant mesothelioma. Chest1988; 94: 1037–9.
39.
FrebourgTLevebourgGDelpechBSerum hyaluronate in malignant pleural mesothelioma. Cancer1987; 59: 2104–7.
40.
DahlISMSolheimOPEriksteinBA longitudinal study of hyaluronan level in the serum of patients with malignant mesothelioma under treatment: Hyaluronan as an indicator of progressive disease. Cancer1989; 63: 68–73.
41.
RobozJGreavesJSidesDHyaluronic acid content of effusions as a diagnostic aid for malignant mesothelioma. Cancer Res1985; 45: 1850–4.
42.
CooperEHForbesMA. Serum hyaluronic acid levels in cancer. Brit J Cancer1988; 58: 668–9.
43.
ManleyGWarrenC.Serum hyaluronic acid in patients with disseminated neoplasm. J Clin Path1987; 40: 626–30.
44.
KumarSWestDCPontingJMSera of children with renal tumours contain low molecular mass hyaluronic acid. Int J Cancer1989; 44: 445–8.
45.
BabaS.Significance of urinary hyaluronate assays in the diagnosis of bladder carcinoma II. Hyaluronate in patients with bladder carcinoma. Nippon Hinyokika Gakkai Zasshi1983; 74: 1362–9.
46.
HallgrenRAEnstrom-LaurentANisbethU.Circulating hyaluronate in uremia, a potential marker of altered metabolism of connective tissue. Nephron1987; 46: 150–4.
47.
WestDCKumarS.The effect of hyaluronate and its oligosacchardides on endothelial cell proliferation and monolayer integrity. Exp Cell Res1989, in press.
48.
HenriksenJHBentsenKDLaurentL.Splanchnic and renal extraction of circulating hyluronan in patients with alcoholic liver disease. J Hepatol1988; 6: 158–66.
49.
FrebourgTDelpechBBercoffESerum hyaluronate in liver diseases: Study by enzymoimmunological assay. Hepatology1986; 6: 392–5.
50.
FraserJREngstrom-LaurentANybergARemoval of hyaluronic acid from the circulation in rheumatoid disease and primary biliary cirrhosis. J Lab Clin Med1986; 107: 79–85.
51.
NybergAEngstrom-LaurentALoofL.Serum hyaluronate in primary biliary cirrhosis—a biochemical marker for progressive liver disease. Hepatology1988; 8: 142–6.
52.
RathboneBJBramleyPNCooperEHSerum hyaluronate as a marker of hepatic derangement in paracetamol induced liver disease. Ass Clin Biochemists National Meeting1989. Association of Clinical Biochemists. Abstract 181.
53.
SnoverDZSibleyRKFreeseDKOrthotopic liver transplantation: A pathological study of 63 liver biopsies from 17 patients with special reference to diagnostic features of rejection and natural history of rejection. Hepatology1984; 4: 123–30.
54.
AdamsDHWangLHubscherSCHepatic endothelial cells. Targets of allograft rejections?Transplantation1989; 47: 479–82.
55.
PollardSCCalneRYMetcalfeSMSerum hyaluronate in liver transplantation. Assn Clin Biochemists National Meeting1989. Association of Clinical Biochemists. Abstract 180.
56.
LevesqueHDelpecheDLe-LoetXSerum hyaluronate in rheumatoid arthritis: Study by affino-immunoenzymatic assay. Br J Rheumatol1988; 27: 445–9.
57.
Hrslev-PetersenKBentsenKDEngstrom-LaurentASerum amino terminal type III procollagen peptide and serum hyaluronan in rheumatoid arthritis: Relation to clinical and serological parameters of inflammation during 8 and 24 months' treatment with levamisole. Ann Rheum Dis1988; 47: 116–26.
58.
ButlerDMVittiGFLeizerTStimulation of hyaluronic acid levels of human synovial fibroblasts by recombinant human tumour necrosis factor beta (lymphotoxin) interleukin-1 alpha and interleukin-1 beta. Arthritis Rheum1988; 31: 1281–9.
59.
Engstom-LaurentLHallgrenR.Circulating hyaluronic acid levels vary with physical activity in healthy subjects and in rheumatoid arthritis patients. Relationship to synovitis and morning stiffness. Arthritis Rheum1987; 30: 1333–8.
60.
KonnoKAraiHMotomiyaMA biochemical study on glycosaminoglycans (mucopolysaccharides) in emphysematous and aged lungs. Ann Rev Resp1982; 126: 797–801.
61.
BjermerLEngstrom-LaurentALundgrenRHyaluronate and type III procollagen peptide concentrations in bronchoalveolar lavage fluid as markers of disease activity in farmer's lung. Br Med J1987; 295: 803–6.
62.
HallgrenRSammelssonTLaurentTCAccumulation of hyaluronan (hyaluronic acid) in the lung in adult respiratory distress syndrome. Am Rev Resp Dis1989; 139: 682–6.
63.
EklundAHallgrenRBlaschkaEHyaluronate in bronchoalveolar lavage fluid in sarcoidosis and its relationship to alveolar cell populations. Europ J Resp Dis1987; 71: 30–6.
64.
BjermerJLundgrenRHallgrenR.Hyaluronan and type III procollagen in bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis. Thorax1989; 44: 126–31.
65.
GressnerAMHaarmannR.Regulation of hyaluronate synthesis in liver fat storing cell cultures by Kupffer cells. J Hepatol1988; 7: 310–18.
66.
McGaryCTRajaRHWeigelRH. Endocytosis of hyaluronic acid by rat liver endothelial cells: Evidence for receptor recycling. Biochem J1989; 257: 875–84.
